Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

How I treat NTRK gene fusion-positive cancers

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Lassen, Ulrik. / How I treat NTRK gene fusion-positive cancers. I: ESMO Open. 2019 ; Bind 4, Nr. Suppl 2. s. e000612.

Bibtex

@article{9c93bdb8c5fc43e5bad6bbaa303832e9,
title = "How I treat NTRK gene fusion-positive cancers",
abstract = "NTRK fusions are found at low frequencies (commonly <1{\%}) in a range of common tumour types and at high frequencies (up to or greater than 90{\%}) in rare cancer types (secretory breast carcinoma, mammary analogue secretory carcinoma and infantile fibrosarcoma). The fusions typically occur in a mutually exclusive fashion with other strong mitogenic drivers, and it is of significant importance to identify patients in order to offer transformative treatment with TRK inhibitors. Larotractinib or entrectinib have resulted in fast and durable response with few and reversible adverse events. Even though on-target resistance may occur, second generation TRK inhibitors are in development and have shown promising activity. Diagnostic strategies must be applied, considering available assays and specific tumour types.",
author = "Ulrik Lassen",
note = "{\circledC} Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.",
year = "2019",
doi = "10.1136/esmoopen-2019-000612",
language = "English",
volume = "4",
pages = "e000612",
journal = "E S M O Open",
issn = "2059-7029",
publisher = "BMJ Publishing Group",
number = "Suppl 2",

}

RIS

TY - JOUR

T1 - How I treat NTRK gene fusion-positive cancers

AU - Lassen, Ulrik

N1 - © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

PY - 2019

Y1 - 2019

N2 - NTRK fusions are found at low frequencies (commonly <1%) in a range of common tumour types and at high frequencies (up to or greater than 90%) in rare cancer types (secretory breast carcinoma, mammary analogue secretory carcinoma and infantile fibrosarcoma). The fusions typically occur in a mutually exclusive fashion with other strong mitogenic drivers, and it is of significant importance to identify patients in order to offer transformative treatment with TRK inhibitors. Larotractinib or entrectinib have resulted in fast and durable response with few and reversible adverse events. Even though on-target resistance may occur, second generation TRK inhibitors are in development and have shown promising activity. Diagnostic strategies must be applied, considering available assays and specific tumour types.

AB - NTRK fusions are found at low frequencies (commonly <1%) in a range of common tumour types and at high frequencies (up to or greater than 90%) in rare cancer types (secretory breast carcinoma, mammary analogue secretory carcinoma and infantile fibrosarcoma). The fusions typically occur in a mutually exclusive fashion with other strong mitogenic drivers, and it is of significant importance to identify patients in order to offer transformative treatment with TRK inhibitors. Larotractinib or entrectinib have resulted in fast and durable response with few and reversible adverse events. Even though on-target resistance may occur, second generation TRK inhibitors are in development and have shown promising activity. Diagnostic strategies must be applied, considering available assays and specific tumour types.

U2 - 10.1136/esmoopen-2019-000612

DO - 10.1136/esmoopen-2019-000612

M3 - Review

VL - 4

SP - e000612

JO - E S M O Open

JF - E S M O Open

SN - 2059-7029

IS - Suppl 2

ER -

ID: 58969784